https://pittplusme.org/study/1952
Lenacapavir (LEN) for the Prevention of HIV-infection – Healthy Volunteers
STUDY BASICS
Are you an HIV-negative woman who has never used PrEP (Pre-Exposure Prophylaxis)? Are you 18-50 years old? You may be able to participate in a study of an experimental drug named Lenacapavir (LEN) being developed to prevent human immunodeficiency virus (HIV) infection. This study involves at least 27 visits over about 2 years. Compensation is provided.
IRB: SSU00122451
- Gilead Sciences - GS-US-528-5744, A Phase 1, Open-Label, Single-Arm, Single-Dose Study to Evaluate the Pharmacokinetics and Distribution of Long-Acting HIV Capsid Inhibitor, Lenacapavir (LEN), into Rectal and Female Genital Tract Tissues in HIV-Seronegative Participants (Pro00043856)
AGE:
18-50
SEX ASSIGNED AT BIRTH:
Female
DURATION:
About 2 years
VISITS:
At least 27
LOCATION:
UPMC Magee-Womens Hospital Clinical Translational Research Center (MWH CTRC) - Oakland
COMPENSATION:
Participants may receive a total of $2980
SHARE STUDY
MEET THE RESEARCHER
Sharon Riddler
Sharon A. Riddler, MD, is Director of Clinical Research in the Division of Infectious Diseases at the University of Pittsburgh. A graduate of the Medical College of Wisconsin and the University of Pittsburgh, Dr. Riddler’s research interests include all aspects of the clinical research process, including protocol development, implementation, and analysis of results.